UCART20x22
B-cell Malignancies
Phase 1/2Active (in collaboration with Servier)
Key Facts
Indication
B-cell Malignancies
Phase
Phase 1/2
Status
Active (in collaboration with Servier)
Company
About Cellectis
Cellectis is a French-American biotech with 25 years of expertise in gene editing, focused on developing next-generation, 'off-the-shelf' CAR T-cell therapies to address significant unmet needs in oncology. The company's core platform combines its flagship TALEN® technology for ultra-precise genome editing with its PulseAgile electroporation system for efficient cellular engineering. With a robust pipeline of allogeneic CAR T candidates and strategic global partnerships with companies like Allogene, Servier, and AstraZeneca, Cellectis aims to transform cancer treatment by making cell therapies more accessible and scalable.
View full company profileTherapeutic Areas
Other B-cell Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| Pirtobrutinib | Eli Lilly | Phase 3 |
| Mezagitamab | Kyowa Kirin | Phase 1/2 |
| Velexbru (tirabrutinib) | Ono Pharmaceutical | Phase 3 |
| KT-413 | Kymera Therapeutics | Phase 1 |
| TG-1701 | TG Therapeutics | Phase 1 |
| TG-1801 | TG Therapeutics | Phase 1 |
| HMPL-760 | HUTCHMED | Phase 1 |
| REC-3565 | Recursion Pharmaceuticals | Phase 1 |
| FT819 | Fate Therapeutics | Phase 1 |
| Prulacabtagene leucel (prula-cel, ADI-001) | Adicet Bio | Phase 1 |